Granzyme B PET Imaging Uncovers Dynamic Patterns of Disease Activity and Therapeutic Response in a Murine Colitis Model
International Journal of Molecular Sciences · 08.05.2026 · 27 (10) · 4194
DOI: 10.3390/ijms27104194 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.05.2026. Verfasst von Arvin Haj-Mirzaian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Precision Imaging, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Me…. Hauptthemen laut MEDLINE: Granzymes, Colitis, Positron-Emission Tomography. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Heidari, Pedram.
Abstract (Originalsprache)
The evaluation of therapeutic response is essential in disease monitoring both for disease status and treatment efficacy in inflammatory bowel disease. Here, we focused on the use of positron emission tomography directed towards granzyme B, a serine protease released by activated cytotoxic T cells and natural killer cells, to evaluate the dynamics of therapeutic response in a colitis model. The goal was to explore the use of granzyme B positron emission tomography as a non-invasive biomarker to monitor disease activity and therapeutic response across several treatments in a dextran sulfate sodium-induced colitis model. C57BL/6 interleukin-10 knockout mice were divided into five groups, including a negative control, positive control and three treatment arms (antitumor necrosis factor, prednisolone, and anti-interleukin-23). The negative control group received regular water, while all other groups were induced with colitis via 3% DSS water for 1 week followed by normal water. Treatments were initiated after colitis was induced (anti-TNF antibody, prednisolone, or anti-IL-23 antibody). Positron emission tomography/computed tomography imaging with 68Ga-NOTA-GZP was performed at baseline (after colitis induction, before therapy), and at 1 and 2 weeks after treatment initiation. Histological analyses were also performed at 1 and 2 weeks after treatment initiation. Gzmb expression and histological changes were also assessed with immunofluorescence staining and bulk ribonucleic acid sequencing. Gzmb-targeted PET imaging revealed distinct longitudinal patterns of colonic tracer uptake related to treatment response. In positive control mice with DSS colitis (no treatment), bowel uptake of 68Ga-NOTA-GZP increased significantly from baseline to week 2. Anti-TNF treatment reduced granzyme B positron emission tomography uptake significantly at week 2, approaching levels seen in negative controls. In prednisolone-treated mice, 68Ga-NOTA-GZP uptake decreased at week 1 but rose significantly by week 2 but still was in normal range. Anti-IL-23 therapy produced a significantly elevated Gzmb PET signal at week 1, followed by a significant decline by week 2 of treatment. The imaging trends were corroborated by tissue analyses and IF staining for Gzmb, which revealed no colonic expression in negative controls and strong Gzmb elevation in positive controls and the prednisolone group but a decreased Gzmb signal in the anti-TNF and late anti-IL-23 groups. Bulk RNA sequencing also supported these findings, with Gzmb gene expression tracking with inflammation severity and NK/T cell abundance and decreasing after effective therapy. Gzmb-targeted PET/CT allows for dynamic and non-invasive assessment of intestinal immune compartment activity and an assessment of therapy in colitis. Gzmb PET was able to detect initial treatment responses of anti-TNF, steroid and anti-IL-23 based on changes in the Gzmb PET signal. This suggests that clinical Gzmb PET imaging may serve as precision imaging for monitoring disease activity with treatment in IBD and help improve patient care by identifying responders and non-responders in real time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Precision Imaging, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
ORCID-Profile: Arvin Haj-Mirzaian, Madeline Ma, Nicole Hofmann, Pedram Heidari
Förderung
- NCI NIH HHS
- Heidari, Pedram
Zitieren
APA
Haj-Mirzaian, A., Ma, M., Hofmann, N., Yuan, H., Mahmood, U., & Heidari, P. (2026). Granzyme B PET Imaging Uncovers Dynamic Patterns of Disease Activity and Therapeutic Response in a Murine Colitis Model. International Journal of Molecular Sciences, 27(10), 4194. https://doi.org/10.3390/ijms27104194
Vancouver
Haj-Mirzaian A, Ma M, Hofmann N, Yuan H, Mahmood U, Heidari P. Granzyme B PET Imaging Uncovers Dynamic Patterns of Disease Activity and Therapeutic Response in a Murine Colitis Model. International Journal of Molecular Sciences. 2026;27(10):4194. doi:10.3390/ijms27104194
BibTeX
@article{HajMirzaian2026,
author = {Haj-Mirzaian, Arvin and Ma, Madeline and Hofmann, Nicole and Yuan, Hushan and Mahmood, Umar and Heidari, Pedram},
title = {Granzyme B PET Imaging Uncovers Dynamic Patterns of Disease Activity and Therapeutic Response in a Murine Colitis Model},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {10},
pages = {4194},
doi = {10.3390/ijms27104194}
}
EUVIMED